The global Chlamydia Diagnostics market revenue is expected to reach US$ 3.69 billion by 2033. The market's expansion could be attributed to growing awareness of the importance of STI testing.

The Chlamydia Diagnostics market in Europe is expected to grow rapidly in the next years due to a variety of causes. The increased prevalence of chlamydia in the region is one of the key market reasons. According to a study conducted by the European Centre for Disease Prevention and Control, the number of reported chlamydia infections in Europe has steadily climbed over the last decade, with over 410,000 cases reported in 2019. The demand for Chlamydia Diagnostics in the region is expected to rise as the prevalence of chlamydia rises.

The availability of enhanced diagnostic tests is another major reason driving the growth of the Chlamydia Diagnostics market. Because of their high sensitivity and specificity, nucleic acid amplification tests (NAATs) are the most often utilised chlamydia diagnostic tests.

Furthermore, because these tests can detect bacterial DNA in a patient's urine, swab, or blood sample, they provide patients with a handy and non-invasive option. Rapid diagnostic technologies, such as the Alere i platform and the Roche Cobas Liat System, have also been developed in recent years, enabling for rapid and accurate chlamydia detection.

Key Takeaways from the Market Study

• NAATs are expected to account for 49% of the Chlamydia Diagnostics market in 2023.
• The global Chlamydia Diagnostics market is expected to grow at an 11% CAGR between 2023 and 2033.
• North America is expected to represent 48% of the Chlamydia Diagnostics market in 2023.
• The European Chlamydia Diagnostics market is expected to account for 46% of the total by 2023.

Competitive Landscape

Key players in the Chlamydia Diagnostics market are Abbott Laboratories, F. Hoffmann-La Roche Ltd, Hologic, Inc., Quidel Corporation, DiaSorin SpA Becton, Dickinson and Company, Bio-Rad Laboratories, Pfizer, Inc., AstraZeneca and Teva Pharmaceuticals

Read More@ https://www.futuremarketinsights.com/reports/chlamydia-diagnostics-market

Key Segments Profiled in the Chlamydia Diagnostics Industry Survey

Test Type:

• Culture Tests
• Nucleic Acid Amplification Tests (NAAT)
• Direct Fluorescent Antibody Tests
• Serology Tests

End User:

• Hospitals
• Clinics
• Diagnostic Centres